Saturday 17 October 2026
Export TELA’s income statement to Excel — free account
TELA Bio, Inc.
TELA Healthcare Medical Devices
TELA Bio, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $80.3 million, up 15.8% from fiscal 2024. In the quarter to June 2026, revenue fell 4.49%, EPS grew 9.09%, free cash flow fell 17.7% and total debt rose 35.5%, each against the same quarter a year earlier. Revenue growth for five consecutive years; insiders bought in the last twelve months.
0.98
0.03
−2.97%
Follow TELA
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
0.88 | 0.69 | 0.44 | 0.54 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(11.83) | (11.38) | (3.18) | (4.59) | |
P/B ratio |
43.47 | 8.78 | 0.00 | 0.00 | |
Price to Tangible BV |
657.08 | 11.18 | 0.00 | 0.00 | |
EV/Sales |
1.07 | 0.79 | 0.68 | 0.90 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(2.68) | (2.25) | (1.86) | (2.31) | |
EV/FCF |
(2.40) | (2.01) | (1.66) | (2.08) | |
Quick Ratio |
2.41 | 3.40 | 2.76 | 2.20 | |
Current Ratio |
3.30 | 4.20 | 3.61 | 2.99 | |
Net Debt/EBITDA |
(1.61) | (0.75) | (1.59) | (2.85) | |
Debt/Assets |
67.37% | 68.35% | 79.93% | 93.88% | |
Debt/Equity |
26.65 | 8.82 | (10.74) | (3.53) | |
Asset Turnover |
1.34 | 0.96 | 1.10 | 1.26 | |
Operating CF/Net income |
0.66 | 0.54 | 0.91 | 0.83 | |
Capex/Depreciation |
(0.85) | (0.40) | (0.45) | (0.22) | |
Interest Coverage |
(6.29) | (4.06) | (5.13) | (4.47) | |
Research and Development Expense of Revenue |
11.35% | 10.20% | 12.29% | 14.12% | |
Selling, General and Administrative Expense of Revenue |
92.68% | 87.57% | 108.63% | 106.28% | |
Intangible Assets out of Total Assets |
0.02 | 0.02 | 0.02 | 0.02 | |
Share Based Compensation of Revenue |
4.62% | 3.89% | 4.28% | 3.18% | |
Graham Net Nets |
(0.06) | 0.01 | (0.30) | (0.49) | |
Graham Number |
0.00 | 0.00 | 1.27 | 2.19 | |
Earnings Yield |
(59.73%) | (70.34%) | (127.42%) | (102.67%) | |
Free Cash Flow Yield |
(50.98%) | (57.16%) | (93.52%) | (80.40%) | |
Revenue per Share |
0.46 | 0.44 | 0.33 | 0.34 | |
Operating CF per Share |
(0.13) | (0.10) | (0.20) | (0.16) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.13) | (0.11) | (0.20) | (0.16) | |
Cash per Share |
0.65 | 1.08 | 0.69 | 0.53 | |
Shareholders Equity per Share |
0.03 | 0.13 | (0.09) | (0.28) | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.03 | 0.13 | (0.09) | (0.28) | |
Free Cash Flow |
(5.93) | (4.96) | (11.29) | (9.44) | |
Working Capital |
39.07 | 57.61 | 46.47 | 36.27 | |
Capital Expenditures |
(0.21) | (0.09) | (0.12) | (0.06) | |
Net Current Asset Value |
(3.98) | 0.48 | (10.79) | (21.11) | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.01 | 0.00 | 0.01 | 0.00 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
11.25 | 10.22 | 10.14 | 10.44 | |
Average Payables |
2.43 | 2.23 | 3.95 | 2.31 | |
Average Inventory |
12.58 | 11.90 | 12.87 | 11.22 | |
Average Assets |
57.30 | 83.99 | 73.57 | 63.64 | |
Average Common Equity |
(2.36) | 17.39 | 6.46 | (3.34) |
Columns are period end dates